Denis Chem Lab Ltd
Incorporated in 1982, Denis Chem Lab Ltd does manufacturing of Pharmaceuticals Transfusion Solution in Bottles[1]
- Market Cap ₹ 139 Cr.
- Current Price ₹ 100
- High / Low ₹ 233 / 88.0
- Stock P/E 13.7
- Book Value ₹ 59.4
- Dividend Yield 2.50 %
- ROCE 20.1 %
- ROE 14.6 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 33.2%
Cons
- Promoter holding is low: 39.0%
- Company has a low return on equity of 12.0% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
55 | 67 | 75 | 98 | 112 | 107 | 123 | 135 | 109 | 136 | 161 | 167 | 172 | |
49 | 60 | 66 | 89 | 98 | 95 | 110 | 120 | 99 | 122 | 142 | 146 | 153 | |
Operating Profit | 6 | 6 | 9 | 8 | 14 | 12 | 14 | 15 | 10 | 14 | 19 | 21 | 19 |
OPM % | 11% | 9% | 12% | 9% | 12% | 11% | 11% | 11% | 9% | 11% | 12% | 13% | 11% |
0 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 1 | 1 | 1 | 2 | |
Interest | 2 | 3 | 5 | 7 | 6 | 5 | 3 | 3 | 2 | 1 | 1 | 1 | 1 |
Depreciation | 1 | 1 | 4 | 6 | 7 | 6 | 6 | 7 | 6 | 6 | 8 | 7 | 7 |
Profit before tax | 3 | 2 | 0 | -3 | 2 | 2 | 6 | 6 | 3 | 9 | 11 | 15 | 14 |
Tax % | 34% | 41% | 78% | 30% | 37% | -5% | -7% | 26% | 27% | 30% | 28% | 26% | |
2 | 1 | 0 | -4 | 1 | 2 | 6 | 4 | 2 | 6 | 8 | 11 | 10 | |
EPS in Rs | 3.11 | 1.17 | 0.07 | -4.16 | 0.89 | 1.54 | 4.58 | 3.03 | 1.63 | 4.51 | 5.66 | 8.04 | 7.28 |
Dividend Payout % | 18% | 0% | 0% | 0% | 0% | 0% | 22% | 0% | 46% | 33% | 35% | 31% |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 6% |
3 Years: | 15% |
TTM: | 2% |
Compounded Profit Growth | |
---|---|
10 Years: | 24% |
5 Years: | 15% |
3 Years: | 70% |
TTM: | 10% |
Stock Price CAGR | |
---|---|
10 Years: | 12% |
5 Years: | 25% |
3 Years: | 10% |
1 Year: | -43% |
Return on Equity | |
---|---|
10 Years: | 8% |
5 Years: | 10% |
3 Years: | 12% |
Last Year: | 15% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 2 | 3 | 9 | 9 | 12 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
Reserves | 7 | 6 | 8 | 7 | 18 | 36 | 43 | 45 | 48 | 53 | 58 | 66 | 69 |
17 | 31 | 48 | 44 | 37 | 25 | 23 | 14 | 9 | 3 | 2 | 1 | 4 | |
10 | 12 | 17 | 24 | 27 | 26 | 26 | 25 | 22 | 27 | 25 | 28 | 31 | |
Total Liabilities | 35 | 52 | 81 | 85 | 94 | 101 | 106 | 97 | 92 | 96 | 99 | 109 | 118 |
10 | 9 | 42 | 40 | 44 | 40 | 50 | 46 | 41 | 42 | 35 | 38 | 36 | |
CWIP | 0 | 9 | 0 | 10 | 1 | 5 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
25 | 34 | 39 | 35 | 49 | 56 | 55 | 52 | 51 | 55 | 62 | 72 | 81 | |
Total Assets | 35 | 52 | 81 | 85 | 94 | 101 | 106 | 97 | 92 | 96 | 99 | 109 | 118 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-1 | -2 | 14 | 21 | 7 | 11 | 8 | 13 | 8 | 17 | 16 | 18 | |
-1 | -9 | -28 | -13 | -1 | -16 | -2 | -2 | -1 | -10 | -11 | -15 | |
4 | 12 | 13 | -7 | -0 | 1 | -5 | -14 | -6 | -7 | -4 | -4 | |
Net Cash Flow | 1 | 0 | -1 | 1 | 5 | -4 | 1 | -3 | 1 | -0 | 1 | -1 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 111 | 91 | 123 | 85 | 104 | 105 | 106 | 94 | 110 | 85 | 71 | 69 |
Inventory Days | 40 | 37 | 40 | 39 | 35 | 52 | 50 | 51 | 60 | 50 | 39 | 43 |
Days Payable | 60 | 53 | 81 | 119 | 136 | 150 | 102 | 108 | 103 | 99 | 79 | 90 |
Cash Conversion Cycle | 90 | 75 | 81 | 4 | 3 | 8 | 55 | 37 | 67 | 36 | 31 | 22 |
Working Capital Days | 67 | 100 | 61 | 4 | 39 | 47 | 59 | 55 | 81 | 54 | 44 | 39 |
ROCE % | 22% | 16% | 11% | 5% | 12% | 9% | 11% | 11% | 6% | 14% | 16% | 20% |
Documents
Announcements
-
Changes To The Email And Website Address Of Registrar And Share Transfer Agent ('RTA') Of The Company.
18 Apr - Update of RTA email and website addresses
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
5 Apr - Certificate under Regulation 74(5) for Q1 2025.
-
Closure of Trading Window
21 Mar - Closure of trading window from April 1, 2025.
-
Integrated Filing (Financial)
14 Feb - Outcome of Board Meeting and financial results for Q3 2024.
-
Results-Financial Results For The Quarter Ended On December 31, 2024
14 Feb - Outcome of Board Meeting and financial results for Q3 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
DCLL manufactures and markets sterile Intravenous injectibles in Glass and Plastic Bottles for human and veterinary consumption. It also manufactures products on contract basis for multinational pharmaceutical companies who market them under their own brands. Company has a fully equipped in-house Quality Control Laboratory having different interdepartments for Chemical Testing, Physico-Chemical Testing, Microbiological Testing, Pyrogens Testing, Sterility Testing and Toxicity Testing. All raw materials, packaging materials, in process testing and finished stocks are tested in-house.